Merck announced today that the phase 3 trial evaluating Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine and platinum-based chemotherapy has met its dual primary endpoint of overall survival (OS) as first-line treatment for patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma.
The results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.
'Patients diagnosed with advanced gastric cancer often face a poor prognosis, underscoring the need for treatment options that can prolong patients' lives,' said Dr Marjorie Green, Senior Vice President at Merck Research Laboratories.
''These results are encouraging and build on the positive progression-free survival, overall response rate and duration of response data from this study,'' she added.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (20%);
- sale of animal health products (9.2%);
- other (1.4%).
Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
